Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase NA 1

Status

Completed 75Unknown 35Recruiting 21Terminated 18Not yet recruiting 7Active not recruiting 7Withdrawn 3Suspended 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Epirubicin × Clear all
NCT06829199 2026-02-19

MK-5890-003

Merck Sharp & Dohme LLC

Phase 2 Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02067416 2023-02-02

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

The Methodist Hospital Research Institute

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT01205217 2017-06-07

ELATE

GlaxoSmithKline

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡